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Abstract
Background: Diphtheria-tetanus-whole-cell pertussis (DTPw)-based combination vaccines are an attractive option
to rapidly achieve high coverage and protection against other important pathogens, such as hepatitis B virus (HBV)
and Haemophilus influenzae type B (Hib). To ensure adequate antigen supply, GlaxoSmithKline Biologicals has
introduced a new DTPw antigen source and developed a new DTPw-HBV/Hib combination vaccine containing a
reduced amount of Hib polyribosylribitol phosphate (PRP). This study was undertaken to compare the
immunogenicity and reactogenicity of this new DTPw-HBV/Hib vaccine with a licensed DTPw-HBV/Hib vaccine
(Tritanrix™-HBV/Hib).
Methods: This was a randomized, partially-blind, multicenter study in three countries in Latin America (Argentina,
Chile and Nicaragua). Healthy children received either the new DTPw-HBV/Hib vaccine (1 of 3 lots; n = 439;
double-blind) or Tritanrix™-HBV/Hib (n = 146; single-blind) co-administered with oral poliovirus vaccine (OPV) at 2,
4 and 6 months, with a booster dose at 18-24 months.
Results: One month after the end of the 3-dose primary vaccination course, the new DTPw-HBV/Hib vaccine was
non-inferior to Tritanrix™-HBV/Hib in terms of seroprotection/vaccine response rates for all component antigens;
≥97.3% and ≥93.9% of subjects in the two groups, respectively, had seroprotective levels of antibodies against
diphtheria, tetanus, hepatitis B and Hib and a vaccine response to the pertussis component. Persistence of
antibodies against all vaccine antigens was comparable between groups, with marked increases in all antibody
concentrations after booster administration in both groups. Both vaccines were generally well-tolerated as primary
and booster doses.
Conclusions: Results confirm the suitability of this new DTPw-HBV/Hib vaccine comprising antigens from a new
source and a reduced PRP content for inclusion into routine childhood vaccination programs.
Trial registration: http://www.clinicaltrials.gov NCT00332566.
Background
Combined diphtheria-tetanus-whole cell pertussis
(DTPw) vaccines remain the cornerstone of childhood
vaccination programs in Latin America and many other
parts of the world [1]. The addition of new antigens to
existing vaccines with established high coverage rates is
an efficient method of rapidly achieving high coverage
and protection against other important pathogens with
minimum impact on vaccination logistics and cost [2-4].
Hepatitis B (HBV) and Haemophilus influenzae type b
(Hib) infections remain endemic in many parts of the
world, causing disease that can readily be prevented by
vaccination [5,6]. Although universal vaccination of
infants against HBV and Hib has been recommended by
the World Health Organization (WHO) since 1992 and
1996, respectively [7-9], uptake of both vaccines is
incomplete. Lack of appropriate combination vaccines
and difficulties with vaccine supply have been identified
as key factors contributing to this slow uptake [10].
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Rixensart, Belgium), a combined DTPw and hepatitis B
vaccine, has been available since the mid-1990s [11].
This vaccine can be mixed with a conjugated Hib vac-
cine (Hiberix™; GSK Biologicals) and administered as a
single injection (Tritanrix™-HBV/Hib) [11,12]. In order
to address the increasing international demand for
DTPw-based combination vaccines, GSK Biologicals has
recently introduced a new source of DTPw antigens and
has developed a new DTPw-HBV/Hib combination vac-
cine containing a reduced amount of Hib capsular poly-
ribosylribitol phosphate (PRP) (2.5 μgp e r0 . 5m Ld o s e
instead of the 10 μg PRP contained in Tritanrix™-HBV/
Hib). DTPw-based combination vaccines with reduced
PRP antigen content have been shown to be non-
inferior to those with higher PRP antigen content in
terms of immune response to all component antigens
after primary and booster vaccination [13-18].
The ability to co-administer DTPw-based combination
vaccines with other routine vaccines would be convenient
for both medical staff and vaccine recipients. Studies
have shown the potential for co-administration of com-
bined DTPw-based combination vaccines with other
pediatric vaccines, including rotavirus vaccine and oral
poliovirus vaccine (OPV) [19]. This study was undertaken
to assess the immunogenicity and reactogenicity of GSK
Biological’s new DTPw-HBV/Hib vaccine compared with
Tritanrix™-HBV/Hib when co-administered with OPV in
healthy Latin American infants at 2, 4 and 6 months.
Antibody persistence and immune response to a booster
dose at 18-24 months of age was also assessed.
Methods
Study design and subjects
This was a randomized, partially-blind, multicenter
study in three countries in Latin America (Argentina,
Chile and Nicaragua) between August 2004 and Septem-
ber 2005. The study was approved by the appropriate
local ethics committees and conducted in accordance
with the Declaration of Helsinki and Good Clinical
Practice guidelines. Healthy male and female infants
born after a normal gestation period (between 36-42
weeks) were enrolled for first vaccination at 6-10 weeks
of age. In Argentina, mothers of prospective participants
were screened prenatally for the presence of hepatitis B
virus surface antigen (HBsAg). Infants born to anti-
HBsAg seropositive mothers were ineligible for study
participation, but were offered HBV vaccination at birth.
Other exclusion criteria included: previous diphtheria,
tetanus, pertussis, hepatitis B, Hib or polio vaccination
or disease; Bacille Calmette-Guérin vaccine given later
than the first 2 weeks of life; major congenital defects or
serious chronic illness; a history of allergic disease or
reactions likely to be exacerbated by any component of
the vaccine; a history of neurological disease, including
previous seizures; any immune deficiency and prior or
planned use of any blood products, immunoglobulins or
immunosuppressive therapy; and acute illness at the
time of enrolment. Written informed consent was
obtained from the parent or guardian of each infant
prior to study entry.
Subjects were randomized in a 1:1:1:1 ratio to receive
either one of three lots of the new DTPw-HBV/Hib
vaccine or the control vaccine (Tritanrix™-HBV/Hib) co-
administered with OPV at 2, 4 and 6 months of age.
The three different production lots of the new DTPw-
HBV/Hib vaccine were administered in a double-blind
manner. Blinding was single-blind with regard to the
control vaccine group since the appearance of the two
vaccines was not exactly the same. Subjects in Nicaragua
and Argentina who had completed the 3-dose primary
vaccination course were invited to receive a booster
dose of the same DTPw-HBV/Hib combination vaccine
at 18-24 months of age. The booster study took place
between June and October 2006.
Objectives
The two co-primary objectives of this study were to
demonstrate both lot-to-lot-consistency of the new
DTPw-HBV/Hib vaccine and non-inferiority of the new
DTPw-HBV/Hib vaccine to Tritanrix™-HBV/Hib in
terms of antibody response one month after the third
primary vaccine dose. For all vaccine antigens, antibody
persistence was assessed prior to booster administration
and antibody responses were assessed one month after
administration of the booster dose.
Vaccines
All vaccines were manufactured by GSK Biologicals. The
diphtheria and tetanus antigens were sourced form GSK
Biologicals Korlatolt Felelossegu Tarsasag (Hungary) and
Pw was obtained from Commonwealth Serum Labora-
tory Ltd. (Australia) for the new DTPw-HBV/Hib vac-
cine. Both vaccines contained ≥30 international units
(IU) diphtheria toxoid, ≥60 IU tetanus toxoid, ≥4I U
killed Bordetella pertussis,a n d1 0μgH B s A g .T h en e w
DTPw-HBV/Hib vaccine contained 2.5 μg of Hib capsu-
lar PRP polysaccharide conjugated to 5-10 μgt e t a n u s
toxoid. Tritanrix™-HBV/Hib contained 10 μgo fH i b
capsular PRP polysaccharide conjugated to 20-40 μg
tetanus toxoid. Both vaccines were administered as a 0.5
mL intramuscular injection into the anterolateral region
of the left thigh. All subjects received OPV concomi-
tantly with each primary dose.
Serology
Blood samples were collected prior to administration of
the first vaccine dose and one month after completion
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taken before and one month after administration of the
booster dose. Samples were stored at -20°C until testing
at GSK Biologicals’ central laboratory in Rixensart, Bel-
gium. Concentrations of antibodies against all vaccine
antigens were determined by enzyme-linked immuno-
sorbent assay (ELISA). Assay cut-offs were 0.1 IU/mL
for diphtheria and tetanus, 15 IU/mL for Bordetella per-
tussis toxin (BPT), 10 mIU/mL for HBsAg and 0.15 μg/
mL for PRP. Pre-booster samples that were negative by
ELISA were retested with the more sensitive in vitro
neutralization assay on Vero cells with a cut-off of 0.016
mIU/ml.
With the exception of anti-BPT, antibody concentra-
tions equal to or greater than the assay cut-off were
considered to be protective. As no correlate of protec-
tion is established for B. pertussis, a vaccine response to
this vaccine component was defined. For primary vacci-
nation, a pertussis vaccine response was defined as the
appearance of anti-BPT antibodies in initially seronega-
tive subjects, or the presence of a post-vaccination anti-
body concentration greater than or equal to the initial
pre-vaccination concentration. A booster response
against the pertussis component was defined as the
appearance of anti-BPT antibodies in pre-booster sero-
negative subjects, or at leas ta2 - f o l di n c r e a s ei na n t i -
BPT antibody concentration in subjects seropositive
prior to boosting.
Reactogenicity and safety
Parents/guardians used diary cards to record the occur-
rence of solicited local (pain, redness and swelling at the
site of injection) and general (drowsiness, fever [defined
as rectal temperature ≥38°C], irritability and loss of
appetite) symptoms during a 4-day follow-up period
after each vaccination. Intensity of symptoms was
graded on a scale of 0-3. Grade 3 symptoms were
defined as follows: for local pain as crying when limb is
moved or a spontaneously painful limb; for local redness
and swelling as diameter > 20 mm; for fever as rectal
temperature > 40.0°C; and for all other symptoms as
preventing normal daily activities. All other (unsolicited)
adverse events were recorded for a period of 30 days
after each vaccination. Serious adverse events (SAEs)
were recorded during the entire study period. All soli-
cited local symptoms were considered causally related to
vaccination. Causality of solicited general symptoms,
unsolicited symptoms and SAEs was assessed by the
investigator.
Statistical analysis
T h et a r g e ts a m p l es i z ew a s5 0 0e v a l u a b l es u b j e c t sf o r
immunogenicity (125 subjects per vaccine group). Con-
sidering that approximately 15% of enrolled subjects
might withdraw or be unevaluable for immunogenicity;
the target enrolment size was 600 subjects (150 subjects
per vaccine group).
Analysis of immunogenicity was performed on the
according-to-protocol (ATP) cohort and the analysis of
safety was performed on the total vaccinated cohort.
Seroprotection rates against diphtheria, tetanus,
HBsAg and PRP and vaccine response rates to BPT
were calculated with 95% CIs. Standardized asymptotic
95% CIs for the differences in seroprotection/vaccine
response rates between the pooled DTPw-HBV/Hib
groups and the Tritanrix™-HBV/Hib group one month
after the third primary vaccine dose were computed.
The response to the new DTPw-HBV/Hib vaccine was
considered non-inferior to that of the control vaccine if
the upper limit of the 95% CI for the absolute difference
between groups was lower than 10% for D, T, PRP and
HBs. GMCs with 95% CI were calculated by taking the
log-transformation of individual concentrations and cal-
culating the anti-log of the mean of these transformed
values. Antibody concentrations below the assay cut-off
were given an arbitrary value of half the cut-off value
for the purpose of GMC calculation. For, D, T, PRP and
HBs antigens, 95% CIs for the GMC ratio (control over
pooled DTPw-HBV/Hib groups) one month after pri-
mary vaccination were computed using an ANOVA
model on the logarithm in base 10 (log10) transforma-
tion of the concentrations using the vaccine group as
covariate, while for pertussis, the 95% CI for the GMC
ratio was computed using an ANCOVA model with the
vaccine group and the log10 concentrations prior to vac-
cination as covariates.
The incidence of solicited local and general symptoms
(any or Grade 3 intensity) was calculated with exact 95%
CI. Differences between groups were compared using
two-sided Fisher exact tests. P-values <0.05 were consid-
ered as possibly indicative of a statistically significant
difference between groups.
The statistical analyses were performed using the Sta-
tistical Analysis Systems (SAS) version 8.2 on Windows
XP Professional and StatXact-5 procedure on SAS.
Results
A total of 585 subjects were enrolled and received pri-
mary vaccination (439 in the DTPw-HBV/Hib group
and 146 in the Tritanrix™-HBV/Hib group). Of these,
147 subjects received booster vaccination at 18-24
months of age (113 and 34 subjects in the two groups,
respectively). The relatively low proportion of subjects
evaluated for booster vaccination is due to only two
countries out of three (Argentina and Nicaragua) parti-
cipating in the booster study. The mean (±SD) age of
the total cohort at the time of first vaccination was 7.8
(±1.12) weeks, 52.0% of subjects were male and 56.6%
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time of the booster dose was 18.9 (±0.7) months and
59.9% of subjects were male. The population was predo-
minantly American Hispanic (78.2%); the other subjects
were White/Caucasian. No clinically significant differ-
ences in demography were seen between groups. Subject
disposition is summarized in Figure 1.
Immunogenicity
Seroprotection/vaccine response rates and antibody
GMCs for all vaccine antigens are shown in Table 1. The
new DTPw-HBV/Hib vaccine was found to be non-infer-
ior to Tritanrix™-HBV/Hib in terms of seroprotection
against diphtheria, tetanus, HBs and PRP antigens follow-
ing primary vaccination. One month after completion of
the 3-dose primary course, 99.0% of subjects in the
DTPw-HBV/Hib group and 100% of those in the Tritan-
rix™-HBV/Hib group had anti-PRP antibody concentra-
tions ≥0.15 μg/mL, with anti-PRP antibody
concentrations ≥1.0 μg/mL in 97.3% and 100% of subjects
in the two groups, respectively. At least 97.7% of subjects
in the DTPw-HBV/Hib group and 93.9% of those in the
Tritanrix™-HBV/Hib group had seroprotective levels of
antibodies against diphtheria, tetanus and hepatitis B and
a vaccine response to the pertussis component at this
time. Post-primary vaccination GMCs for anti-diphtheria
and anti-HBs antibodies were significantly higher (non-
overlapping CI) in the DTPw-HBV/Hib group than in
the Tritanrix™-HBV/Hib control group, while anti-PRP
GMC was significantly higher in the Tritanrix™-HBV/Hib
group than in the DTPw-HBV/Hib group (21.4 and 12.5
μg/mL, respectively; non-overlapping CI).
Prior to booster administration at 18-24 months, anti-
PRP antibody concentrations remained ≥0.15 μg/mL in
95.5% of subjects in the DTPw-HBV/Hib and 100% of
those in the Tritanrix™-HBV/Hib group. More than
81.7% and 75.8% of subjects in the two groups, respec-
tively, still had seroprotective levels of antibodies to
diphtheria (by ELISA), tetanus and hepatitis B at this
time, with 32.7% and 36.4% of subjects remaining seropo-
sitive for anti-BPT antibodies (data not shown). Testing
of seronegative samples by the Vero cell neutralisation
assay showed a global seroprotection rate against
diphtheria of 90.5% and 82.4% in the two groups, respec-
tively. No differences in pre-booster antibody GMCs
were seen between the two groups, with the exception of
a significantly higher anti-PRP GMC in the Tritanrix™-
HBV/Hib group (2.1 compared with 1.0 μg/mL in the
DTPw-HBV/Hib group; non-overlapping CI).
A marked booster response to all vaccine antigens was
observed in both groups. One month after booster
administration, all subjects had anti-PRP antibody
concentrations ≥0.15 μg/mL, with anti-PRP antibody
concentrations ≥1.0 μg/mL in all but one subject in the
DTPw-HBV/Hib vaccine group. At least 99.1% of sub-
jects in the DTPw-HBV/Hib group and 97.1% of those
in the Tritanrix™-HBV/Hib group had seroprotective
levels of antibodies against diphtheria, tetanus and hepa-
titis B and a booster response to the pertussis compo-
nent following booster administration. Post-booster
GMCs did not appear to differ between the two groups,
with the exception of anti-PRP GMC which remained
significantly higher in the Tritanrix™-HBV/Hib group
than in the DTPw-HBV/Hib group (66.6 and 33.4 μg/
mL, respectively; non-overlapping CI).
Reactogenicity and safety
The overall incidence of solicited local and general
symptoms following primary and booster doses is shown
in Table 2. Pain was the most frequent local solicited
symptom in both groups. Grade 3 pain appeared to be
more common in the DTPw-HBV/Hib group than in
the Tritanrix™-HBV/Hib group after both primary and
booster doses (21.8% and 15.4% in the two groups,
respectively, following primary vaccination; non-overlap-
ping CI, and 43.4% and 23.5%, respectively, after the
booster dose). Irritability and fever were the most com-
mon general solicited symptoms. One subject in each
group withdrew due to Grade 3 irritability following
administration of the first primary dose. Irritability
occurred more frequently after the booster dose in the
DTPw-HBV/Hib group than in the Tritanrix™-HBV/Hib
group (71.7% versus 47.1%, respectively). The incidence
of fever (rectal temperature ≥38.0°C) was higher in the
DTPw-HBV/Hib group than in the Tritanrix™-HBV/Hib
group following both primary and booster vaccination
(56.9% versus 46.7%; non-overlapping CI and 70.8% ver-
sus 58.8%, respectively). However, the incidence of rectal
temperature ≥40.0°C was low and similar in both groups
after all doses. Very few subjects required medical
advice for solicited symptoms following either primary
or booster doses (Table 2).
The incidence of unsolicited symptoms considered
related to vaccination did not differ between groups
(17.7% of the doses administered in the DTPw-HBV/
Hib group and 17.1% in the Tritanrix™-HBV/Hib group
after primary vaccination and none were reported in
either of the groups after the booster dose). The most
common unsolicited symptom considered related to vac-
cination after primary vaccination was injection site
reactions in both groups. Injection site induration was
reported following 15.9% and 15.6% of the vaccine doses
in the DTPw-HBV/Hib and in the Tritanrix™-HBV/Hib
groups respectively. Two SAEs considered related to
vaccination were reported during the primary course.
Both of these events occurred in the DTPw-HBV/Hib
group and required hospitalization, but resolved without
sequelae. One subject who presented persistent crying
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remained to complete the 3-dose primary vaccination
course. The other subject experienced erythema and
induration at the vaccine injection site six days after
vaccination. The subject was diagnosed as having left
thigh abscess and was treated. Following discharge the
subject recovered, but was subsequently withdrawn from
the study. No SAEs considered related to vaccination
were reported after booster administration.
Discussion
Clinical experience shows DTPw-HBV/Hib combination
vaccines to be an efficient and reliable method of imple-
menting WHO recommendations for controlling
diphtheria, tetanus, pertussis, hepatitis B and Hib infec-
tions on a worldwide basis [11]. For the new vaccine
evaluated in this study, new antigen sources and
reduced antigen content were used to ensure continued
vaccine supply for global mass vaccination campaigns.
This DTPw-HBV/Hib combination vaccine is based on
the same formulation as the licensed Tritanrix™-HBV/
Hib vaccine [12,20], but containing diphtheria, tetanus
and pertussis antigens from an alternative source and a
lower amount of the PRP capsular polysaccharide com-
ponent of Hib (2.5 instead of 10 μg/mL per 0.5 ml
dose). The study was designed and powered for immu-
nogenicity comparison in primary vaccination; booster
evaluation was purely descriptive and conducted in a
Table 1 Seroprotection (SP), vaccine response (VR) rates and GMCs one month post-primary and pre- and one month
post-booster vaccination (ATP immunogenicity cohort)
Post-Primary Pre-Booster Post-Booster
Group N %SP/VR
(95% CI)
GMC
(95% CI)
N %SP
(95% CI)
GMC
(95% CI)
N %SP/BR
(95% CI)
GMC
(95% CI)
Anti-diphtheria (≥0.1
IU/mL)
DTPw-HBV/Hib 398 97.7 (95.8,
99.0)
2.093§ (1.851,
2.366)
109 81.7 (73.1,
88.4)
0.263 (0.218,
0.316)
110 100 (96.7,
100)
6.755 (5.726, 7.970)
Tritanrix™-HBV/Hib 132 93.9 (88.4,
97.3)
1.350§ (1.077,
1.691)
33 75.8 (57.7,
88.9)
0.214 (0.153,
0.300)
34 100 (89.7,
100)
4.974 (3.197, 7.738)
Anti-tetanus (≥0.1 IU/
mL)
DTPw-HBV/Hib 399 99.7 (98.6,
100)
6.679 (6.084, 7.333) 110 98.2 (93.6,
99.8)
0.652 (0.555,
0.767)
110 100 (96.7,
100)
18.555 (16.406,
20.984)
Tritanrix™-HBV/Hib 131 100 (97.2,
100)
5.884 (4.964, 6.974) 34 100 (89.7,
100)
0.748 (0.564,
0.991)
34 100 (89.7,
100)
15.430 (12.205,
19.507)
Anti-HBs (≥10 mIU/mL)
DTPw-HBV/Hib 400 99.8 (98.6,
100)
2417.5§ (2127.3,
2747.3)
110 94.5 (88.5,
98.0)
126.9 (98.1,
164.2)
110 99.1 (95.0,
100)
19247.5 (14422.5,
25686.6)
Tritanrix™-HBV/Hib 132 97.7 (93.5,
99.5)
1319.3§ (1035.8,
1680.3)
34 94.1 (80.3,
99.3)
97.3 (65.5, 144.3) 34 97.1 (84.7,
99.9)
14366.8 (7612.5,
27114.2)
Anti-PRP (≥0.15 μg/mL)
DTPw-HBV/Hib 400 99.0 (97.5,
99.7)
12.530§ (11.180,
14.043)
110 95.5 (89.7,
98.5)
1.006§ (0.768,
1.319)
110 100 (96.7,
100)
34.364§ (27.563,
42.843)
Tritanrix™-HBV/Hib 132 100 (97.2,
100)
21.393§ (17.971,
25.467)
34 100 (89.7,
100)
2.059§ (1.357,
3.123)
34 100 (89.7,
100)
66.616§ (43.734,
101.468)
Anti-PRP (≥1.0 μg/mL)
DTPw-HBV/Hib 400 97.3 (95.1,
98.6)
- 110 46.4 (36.8,
56.1)
- 110 99.1 (95.0,
100)
-
Tritanrix™-HBV/Hib 132 100 (97.2,
100)
- 34 79.4 (62.1,
91.3)
- 34 100 (89.7,
100)
-
Anti-BPT (VR or BR)
DTPw-HBV/Hib 394* 97.9 (96.0,
99.1)
82.6 (76.7, 89.1) 110 10.9 (9.8, 12.1) 109 99.1 (95.0,
100)
105.1 (93.6, 118.0)
Tritanrix™-HBV/Hib 131 95.4 (90.3,
98.3)
90.5 (77.7, 105.5) 33 11.1 (9.1, 13.7) 34# 100 (89.5,
100)
128.4 (99.2, 166.3)
N = number of subjects with available results; *390 subjects for vaccine response; #33 subjects for booster response.
Vaccine (VR) response to the pertussis component defined as the appearance of antibody concentration ≥15 EL.U/mL in subjects seronegative at pre-vaccination
or maintenance of pre-vaccination antibody concentrations one month after the third dose in initially seropositive subjects prior to primary vaccination.
Booster (BR) response to the pertussis component defined as the appearance of antibody concentration ≥15 EL.U/mL in subjects seronegative at pre-booster or
post-booster antibody concentration two-fold higher than pre-booster antibody concentrations in initially seropositive subjects prior to the booster vaccination.
%SP = percentage of subjects who achieve seropositivity as is described for each antigen; GMC = geometric mean antibody concentration; 95%CI = 95%
confidence interval; § non-overlapping CI.
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nistered with OPV at 2, 4 and 6 months of age, the new
DTPw-HBV/Hib vaccine was found to be non-inferior
to Tritanrix™-HBV/Hib in terms of seroprotection to
the D, T, HBs and PRP vaccine antigens one month
after completion of the 3-dose primary course. Immune
response to all vaccine antigens was within the range
previously reported for this or other similar DTPw-
based vaccines [11-13,15-17,20].
Lot-to-lot consistency for the new DTPw-HBV/Hib
vaccine was demonstrated, i.e., for anti-diphtheria, anti-
tetanus, anti-HBs and anti-PRP, the standardized asymp-
totic 90% confidence intervals (CI) for the absolute dif-
ference between each pair of lots in the percentage of
subjects seroprotected was within [-10%; 10%] and for
anti-BPT, the 90% confidence interval for the ratio of
geometric mean antibody concentrations (GMCs)
between each pair of lots was within [0.5, 2] (data not
shown). Based on these findings, data for the three vac-
cine lots used in this study were pooled for comparison
against the control vaccine.
Antibody GMCs induced by the new DTPw-HBV/Hib
vaccine following primary vaccination were observed
similar to those induced by Tritanrix™-HBV/Hib, with
the exception of anti-PRP GMC. However, almost all
subjects achieved anti-PRP concentrations ≥1.0 μg/mL
(≥97.3%) and post-primary anti-PRP GMCs were high
(> 12.5 μg/mL) in both groups, suggesting that inter-
group differences are unlikely to be of clinical relevance.
A large body of evidence shows reduction of the PRP
Table 2 Incidence (% [95% CI]) of solicited local and general symptoms during the 4 days following primary (overall/
dose) and booster vaccination (Total vaccinated cohort)
Primary doses Booster dose
Solicited symptom DTPw-HBV/Hib
(N = 1274)
Tritanrix™-HBV/Hib
(N = 422)
DTPw-HBV/Hib
(N = 113)
Tritanrix™-HBV/Hib
(N = 34)
Pain
Any 73.4 (70.9, 75.8) 69.4 (64.8, 73.8) 90.3 (83.2, 95.0) 79.4 (62.1, 91.3)
Grade 3 21.8 (19.6, 24.2)§ 15.4 (12.1, 19.2)§ 43.4 (34.1, 53.0) 23.5 (10.7, 41.2)
MA 0.5 (0.2, 1.1) 0.5 (0.1, 1.7) 0 (0.0, 3.2) 0 (0.0, 10.3)
Redness
Any 53.1 (50.4, 55.9)§ 44.1 (39.3, 49.0)§ 48.7 (39.2, 58.3) 44.1 (27.2, 62.1)
>20 mm 17.3 (15.2, 19.5) 12.8 (9.8, 16.4) 14.2 (8.3, 22.0) 11.8 (3.3, 27.5)
MA 0.6 (0.3, 1.2) 0 (0.0, 0.9) 0 (0.0, 3.2) 0 (0.0, 10.3)
Swelling
Any 51.1 (48.3, 53.9) 46.4 (41.6, 51.3) 64.6 (55.0, 73.4) 38.2 (22.2, 56.4)
>20 mm 21.7 (19.4, 24.0) 23.2 (19.3, 27.6) 28.3 (20.2, 37.6) 17.6 (6.8, 34.5)
MA 0.7 (0.3, 1.3) 0.2 (0.0, 1.3) 0.9 (0.0, 4.8) 0 (0.0, 10.3)
Drowsiness
Any 44.3 (41.6, 47.1) 44.1 (39.3, 49.0) 39.8 (30.7, 49.5) 17.6 (6.8, 34.5)
Grade 3 1.5 (0.9, 2.3) 0.9 (0.3, 2.4) 2.7 (0.6, 7.6) 0 (0.0, 10.3)
MA 0.4 (0.1, 0.9) 0.2 (0.0, 1.3) 0 (0.0, 3.2) 0 (0.0, 10.3)
Rectal temperature
Any 56.9 (54.1, 59.6)§ 46.7 (41.8, 51.6)§ 70.8 (61.5, 79.0) 58.8 (40.7, 75.4)
>38.0°C 56.9 (54.1, 59.6)§ 46.7 (41.8, 51.6)§ 38.1 (29.1, 47.7) 14.7 (5.0, 31.1)
>38.5°C 19.6 (17.5, 21.9) 17.5 (14.0, 21.5) 21.2 (14.1, 29.9) 5.9 (0.7, 19.7)
>39.0°C 6.9 (5.6, 8.4) 5.0 (3.1, 7.5) 1.8 (0.2, 6.2) 2.9 (0.1, 15.3)
>39.5°C 2.8 (2.0, 3.9) 3.1 (1.7, 5.2) 0.9 (0.0, 4.8) 0.0 (0.0, 10.3)
>40.0°C 0.5 (0.2, 1.0) 0.7 (0.1, 2.1) 0.0 (0.0, 3.2) 0.0 (0.0, 10.3)
MA 1.2 (0.7, 1.9) 0.5 (0.1, 1.7) 0.0 (0.0, 3.2) 0.0 (0.0, 10.3)
Irritability
Any 67.0 (64.4, 69.6) 65.2 (60.4, 69.7) 71.7 (62.4, 79.8) 47.1 (29.8, 64.9)
Grade 3 5.0 (3.9, 6.4) 6.6 (4.5, 9.4) 9.7 (5.0, 16.8) 0 (0.0, 10.3)
MA 0.7 (0.3, 1.3) 0.7 (0.1, 2.1) 0 (0.0, 3.2) 0 (0.0, 10.3)
Loss of appetite
Any 29.9 (27.4, 32.5) 26.1 (21.9, 30.5) 42.5 (33.2, 52.1) 29.4 (15.1, 47.5)
Grade 3 0.8 (0.4, 1.4) 0.5 (0.1, 1.7) 4.4 (1.5, 10.0) 0 (0.0, 10.3)
MA 0.3 (0.1, 0.8) 0.2 (0.0, 1.3) 0 (0.0, 3.2) 0 (0.0, 10.3)
N = number of doses; MA = medical advice sought for the symptom; § non-overlapping CI.
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Page 7 of 9content of Hib conjugate-based vaccines to have no
negative impact on either immune response or induc-
tion of immune memory to Hib [21-26]. Effective induc-
tion of immune memory was demonstrated with the
reduced-content Hib component used in this DTPw-
HBV/Hib vaccine [14,18]. In our study, a high degree of
antibody persistence and a vigorous booster response
was seen for all vaccine antigens including PRP in both
groups, indicative of effective priming and induction of
immune memory with both vaccines.
The new DTPw-HBV/Hib vaccine was found to have
an acceptable reactogenicity profile. Some differences in
reactogenicity were observed between the two vaccines.
However, since very few subjects in either group sought
medical advice for solicited symptoms it is likely that
any differences had minimal clinical impact. Also, as no
correction for multiplicity of endpoints was applied, sta-
tistically significant differences in reactogenicity should
be interpreted with caution. Very few subjects in this
study failed to receive all planned vaccine doses due to
adverse events (2 in the DTPw-HBV/Hib group and 1 in
the Tritanrix™-HBV/Hib group). Indeed, by eliminating
the need for multiple injections, such combination vac-
cines are likely to promote compliance with infant
immunization schedules [2-4]. In both groups, the inci-
dence of solicited symptoms was higher after the boos-
ter dose than after the primary doses, as has previously
been reported following booster vaccination with
DTPw- and diphtheria-tetanus-acellular pertussis based
vaccines [14,15,17,27,28].
Conclusions
In conclusion, the development of new DTPw-based
combination vaccines is essential for the success of cur-
rent and future childhood mass vaccination programs in
countries where resources are limited. Combining
DTPw vaccines with HBV and Hib performs a key role
in increasing vaccine coverage rates in line with WHO
targets. Results of this study confirm the suitability of
GSK Biologicals’ new DTPw-HBV/Hib vaccine contain-
ing DTPw antigens from a new source and a reduced
quantity of PRP as an alternative to currently licensed
DTPw-based combination vaccines for use as a primary
or booster dose in routine pediatric vaccination
programs.
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